erlotinib hydrochloride has been researched along with Nasopharyngeal Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Q; Zhang, F; Zhang, J; Zhang, Y; Zhou, F; Zou, Q | 1 |
| Chen, JP; Hsu, YB; Lan, MC; Lan, MY; Lu, YJ | 1 |
2 other study(ies) available for erlotinib hydrochloride and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells.
Topics: Chemoradiotherapy; DNA Damage; Erlotinib Hydrochloride; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2020 |
Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Graphite; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Polyethylene Glycols | 2020 |